Cannabinoids from cannabis (Cannabis sativa) are anti-inflammatory and have inhibitory effects on the proliferation of a quantity of tumorigenic cell lines, some of which are mediated by means of cannabinoid receptors. Cannabinoid (CB) receptors are present in human skin and anandamide, an endogenous CB receptor ligand, inhibits epidermal keratinocyte differentiation. Psoriasis is an inflammatory illness also characterised in component by epidermal keratinocyte hyper-proliferation.
We investigated the plant cannabinoids Delta-9 tetrahydrocannabinol, cannabidiol, cannabinol and cannabigerol for their potential to inhibit the proliferation of a hyper-proliferating human keratinocyte cell line and for any involvement of cannabinoid receptors.
A keratinocyte proliferation assay was utilised to assess the impact of therapy with cannabinoids. Cell integrity and metabolic competence confirmed working with lactate-dehydrogenase and adenosine tri-phosphate assays. To identify the involvement of the receptors, precise agonist and antagonist had been utilised in conjunction with some phytocannabinoids. Western blot and RT-PCR evaluation confirmed presence of CB1 and CB2 receptors.
The cannabinoids tested all inhibited keratinocyte proliferation in a concentration-dependent manner. The selective CB2 receptor agonists JWH015 and BML190 elicited only partial inhibition, the non-selective CB agonist HU210 created a concentration-dependent response, the activity of theses agonists had been not blocked by either CB1/CB2 antagonists.
The benefits indicate that whilst CB receptors could have a circumstantial part in keratinocyte proliferation, they do not contribute drastically to this course of action. Our benefits show that cannabinoids inhibit keratinocyte proliferation, and thus help a prospective part for cannabinoids in the therapy of psoriasis.